Form 4: Incyte Principal Accounting Officer Sells Shares Under Pre-Arranged Trading Plan

Incyte Corp's Principal Accounting Officer, Tray Thomas, sold a total of 1,614 shares of common stock in two transactions in late May and early June 2025, pursuant to a Rule 10b5-1 trading plan.

Summary

• Tray Thomas, Principal Accounting Officer of Incyte Corp (INCY), reported two sales of common stock.
• On May 30, 2025, Mr. Thomas sold 963 shares of Incyte common stock at a price of $65.71 per share.
• Following this transaction, Mr. Thomas beneficially owned 22,654 shares of common stock.
• On June 2, 2025, an additional 651 shares of Incyte common stock were sold at a price of $64.88 per share.
• After the second transaction, Mr. Thomas's beneficial ownership decreased to 22,003 shares of common stock.
• The reported transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.
• The total beneficial ownership of 22,003 shares includes an aggregate of 15,406 shares of common stock issuable pursuant to previously reported restricted stock units that have not yet vested.

Sentiment

Score: 5

Explanation: The filing reports routine insider stock sales executed under a pre-arranged 10b5-1 plan, which is generally considered neutral as it's not indicative of new information or a change in sentiment regarding the company's prospects.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not based on new, non-public information, which can mitigate concerns about opportunistic insider selling.

Negatives

• The filing reports insider selling, which, regardless of the reason, can sometimes be perceived negatively by the market as it reduces an insider's direct stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape within the biotechnology or pharmaceutical sectors.

Stakeholder Impact

• Shareholders may note the insider selling, although the execution under a Rule 10b5-1 plan suggests a pre-planned, non-discretionary sale rather than a reaction to recent company developments.

Key Dates

Keywords

Incyte Corp, INCY, Form 4, Insider Trading, Stock Sale, Tray Thomas, Principal Accounting Officer, Rule 10b5-1, Biotechnology, Pharmaceuticals